| Filed On | Filing |
|---|---|
| 07 Oct 2026 | SCHEDULE 13G/A |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 28 May 2026 |
Form 4: Ratcliffe Peter John, Director
Granted 27,492 Share Option (Right to Buy) |
| 28 May 2026 |
Form 4: Pao William, Director
Granted 27,492 Share Option (Right to Buy) |
| 28 May 2026 |
Form 4: Peterson Kristine, Director
Granted 27,492 Share Option (Right to Buy) |
| 28 May 2026 |
Form 4: Kaul Siddharth, Director
Granted 27,492 Share Option (Right to Buy) |
| 28 May 2026 |
Form 4: Herbst Roy Steven, Director
Granted 27,492 Share Option (Right to Buy) |
| 28 May 2026 |
Form 4: Bell John Irving, Director
Granted 27,492 Share Option (Right to Buy) |
| 27 May 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 22 May 2026 | 144 |
| 21 May 2026 | 144 |
| 15 May 2026 | SCHEDULE 13G |
| 15 May 2026 | SCHEDULE 13G/A |
| 08 May 2026 | S-8 |
| 06 May 2026 | 10-Q |
Loading...
